Pinealon 10mg

Pinealon is a 4-residue synthetic peptide composed of glycine, glutamic acid, aspartic acid, and arginine — single-letter sequence GEDR. The molecule sits within the family of short synthetic peptides developed at the St. Petersburg Institute of Bioregulation and Gerontology under V.Kh. Khavinson's research direction. The institute's peptide-bioregulator framework — pursued since the 1970s — hypothesizes that short synthetic peptides can engage tissue-specific gene-expression patterns relevant to cellular aging and neuronal function.

Pinealon specifically has been examined for antioxidant and anti-apoptotic effects in primary neuronal culture and in models of oxidative stress. The molecule has been administered subcutaneously in published rodent-model work, with daily-dosing schedules typical of the broader peptide-bioregulator research framework. Published mechanism work on the compound has examined gene-expression modulation in cultured cells as the proposed primary signaling layer, though specific molecular targets remain incompletely characterized in independent Western literature.

Investigators outside the original developer's research network have published a smaller number of Pinealon-specific studies than is the case for BPC-157, the thymosin-class peptides, or the GLP-1-family compounds. The published Western literature on the compound does not at this writing support firm conclusions about clinical translation, and the molecule has not entered registrational clinical research in any jurisdiction. Ronin Peptides supplies Pinealon as a research-grade reagent for laboratory and bench-research use only.

Buyers should approach the published literature with appropriate calibration: the evidence base is thinner than for compounds with broader Western mechanistic study, much of the primary mechanism work is concentrated within the Khavinson group, and reporting conventions differ from those typical of Western pharmacology journals. The compound nonetheless sees research use as a laboratory probe for tetrapeptide signaling and neuroprotection research questions.

Tetrapeptide mechanism work in the peptide-bioregulator research tradition has examined gene-expression modulation in cultured cells as the proposed primary signaling layer. Investigators in this tradition have used DNA-binding assays and microarray studies of cell preparations exposed to Pinealon, reporting modulation of expression patterns relevant to oxidative-stress response, antioxidant enzyme systems, and pro-apoptotic gene regulation. The specific molecular targets engaged by the peptide remain incompletely characterized in peer-reviewed Western literature — the mechanism framing draws substantially on the Khavinson group's own published models of tetrapeptide intracellular signaling.

In primary neuronal culture preparations, Pinealon has been examined for effects on neuronal survival under oxidative-stress conditions. Reports from the developer's research network have suggested reductions in markers of cellular apoptosis and oxidative damage under specific in vitro conditions. The proposed downstream mechanism centers on antioxidant pathway engagement and modulation of pro-apoptotic gene expression. Independent replication of these findings in laboratories outside the original developer's network is limited at this writing.

The plasma pharmacokinetic profile is not extensively characterized in published Western literature. Subcutaneous administration is the most commonly reported route in available animal-model work. Plasma residence is short relative to the larger acylated peptides — consistent with the small molecular weight (~459 g/mol) and the lack of half-life-extending backbone modifications. Daily-dosing schedules in published rodent work reflect this short residence.

The mechanism framework — small synthetic peptides engaging tissue-specific gene-expression programs — sits methodologically apart from the receptor-agonist framework dominant in Western pharmacology research on peptides like the GLP-1-class or BPC-157. Researchers examining Pinealon may want to evaluate the mechanism framing against current Western expectations for molecular target characterization, replication standards, and effect-size reporting.

Published research on Pinealon has primarily examined three areas. First, in vitro and ex vivo neuronal-protection studies have measured effects on neuronal survival, oxidative-stress markers, and apoptotic-pathway activation in primary neuronal culture and in retinal-tissue culture preparations. Second, behavioral-cognition studies in rodent models have examined memory and learning endpoints — typically maze-task performance and conditioned-response paradigms — following peptide exposure. Third, broader aging-research studies in fly and rodent models have measured lifespan, oxidative-stress markers, and age-related behavioral changes.

Reporting conventions in the original research differ in places from those Western journals typically require. Effect sizes are sometimes reported without confidence intervals; multi-comparison correction is sometimes absent from cross-arm statistical comparisons; effect-size reporting can lack the standardized framing common in Western pharmacology journals. Where independent labs have examined the compound, the reported outcomes have been mixed — some studies have observed effects consistent with the original developer's reports; others have not.

The compound has not entered registrational clinical research anywhere. The published literature does not at this writing support firm conclusions about clinical translation. Research interest has remained as a probe for tetrapeptide signaling mechanisms and as a reference compound in studies of antioxidant peptide pathways, rather than as a candidate compound for clinical advancement.

For researchers planning experiments with Pinealon, the Khavinson group's review papers on tetrapeptide bioregulation provide the most-comprehensive published framing of the proposed signaling mechanism, while independent retinal- and neuronal-protection studies provide the most-replicated cell-culture readouts. Researchers approaching the compound for the first time should calibrate expectations against the depth of available published literature.

Unopened lyophilized vials hold up well under dry ambient conditions, with usable activity persisting for several weeks even without refrigeration. The unopened original vial is the recommended container until the moment of reconstitution. Refrigeration at 2–8 °C extends practical shelf life into months. Long-term archival storage uses −20 °C in a standard laboratory or household freezer.

Keep vials shielded from light, ideally in their original outer packaging. Peptides without backbone modification — Pinealon among them — degrade primarily through peptide-bond hydrolysis under aqueous conditions; the lyophilized form minimizes this pathway.

After reconstitution, refrigerate the solution at 2–8 °C without delay. Working potency for a reconstituted preparation typically holds for several weeks under refrigeration. Past that window, peptide concentration drifts downward through chemical degradation pathways even though the bacteriostatic water's benzyl alcohol still suppresses microbial growth.

When a research timeline extends past the working window, common practice is splitting the reconstituted solution into single-use volumes immediately after reconstitution and freezing those aliquots at −20 °C. Each freeze-thaw cycle damages peptide chains; pre-splitting eliminates the cumulative loss that comes from thawing one bulk vial multiple times. Thaw individual aliquots overnight in a refrigerator and use within a few days of thaw.

The reconstitution diluent is USP-grade bacteriostatic water containing 0.9% benzyl alcohol; see the bacteriostatic water product page for reconstitution-grade water.

Among Russian-developed synthetic peptides, Semax and Selank have accumulated broader Western peer-reviewed primary research than Pinealon and Epithalon. Researchers examining the Khavinson tetrapeptide tradition will find more cross-laboratory replication for the heptapeptides (Semax, Selank) than for the tetrapeptides (Pinealon, Epithalon). The Khavinson tetrapeptides share a common mechanistic framework — gene-expression modulation through proposed direct DNA-binding — that sits methodologically apart from the receptor-agonist framing dominant in Western peptide pharmacology research.

A 10 mg Pinealon vial reconstituted with 2 mL of bacteriostatic water yields a working concentration of 5 mg/mL. Alternative dilutions: 1 mL of diluent gives 10 mg/mL (concentrated stock); 5 mL gives 2 mg/mL (dilute stock).

Reconstitution procedure:

1. Bring both vials — peptide and bacteriostatic water — to room temperature before opening.
2. Sanitise both rubber stoppers with an alcohol swab.
3. Pull the chosen diluent volume into a sterile transfer syringe.
4. Direct the water against the inner wall of the peptide vial as it is injected — never onto the lyophilized cake, since direct impact foams the solution and damages peptide structure at the air-water interface.
5. Invert slowly or swirl gently until everything dissolves. Do not vortex; do not shake.
6. Refrigerate at 2–8 °C the moment reconstitution completes.

A finished preparation should be visually transparent with no suspended particulate. If hazy, treat as degraded or contaminated and discard.

The published Western primary-research literature on Pinealon is more limited than for compounds with broader cross-laboratory mechanistic study. The reference list below reflects that scope. Researchers approaching the compound are encouraged to read the source material directly to evaluate the methodology and reporting conventions used in the Russian peptide-bioregulator research tradition. PMID identifiers are provided where Western MEDLINE-indexed references exist; the Khavinson-group methodology papers in the Russian peptide-research tradition are cited by journal where MEDLINE indexing is partial.

1. Khavinson VK, Linkova NS, Tarnovskaya SI. Short Peptides Regulate Gene Expression. Bull Exp Biol Med. 2016;162(2):288-292. (English translation indexed under the journal's MEDLINE entry.)
2. Khavinson VK, Tarnovskaya SI, Linkova NS, Pronyaeva VE, Shataeva LK, Yakutseni PP. Short cell-penetrating peptides: a model of interactions with gene promoter sites. Bull Exp Biol Med. 2013;154(3):403-410. Khavinson-group methodological framework for tetrapeptide signaling.
3. Anisimov VN, Khavinson VK. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-149. Review of the broader peptide-bioregulator research tradition.
4. Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide regulation of gene expression: A systematic review. Molecules. 2021;26(22):7053. Khavinson-group summary review of the tetrapeptide research framework.
5. Arutjunyan A, Kozina L, Stvolinskiy S, Bulygina Y, Mashkina A, Khavinson V. Pinealon protects the rat offspring from prenatal hyperhomocysteinemia. Int J Clin Exp Med. 2012;5(2):179-185. Pinealon-specific research on prenatal exposure models.